Insider Purchases: Inside the Buy

Tag: ContrarianStocks

A playful digital illustration of a dog wearing glasses and reading a stock chart, symbolizing Freshpet’s stock recovery potential and insider buying activity.

Can Freshpet Make for a Fresh Buy: Insiders & Directors Think So

Freshpet’s stock has tumbled more than 70% from its highs, but insiders keep buying and Wall Street funds are all-in (119% ownership!). With revenue growing, profitability improving, and valuation looking much more reasonable, is this the turnaround treat investors have been waiting for? 🐾🍖

Read entire article

Tags: contrarian investing, ContrarianPlay, ContrarianStocks, DIrector Buying, Director Insider Buying, Freshpet, FRPT, Funanc1al, Funanc1al Edge, Funanc1al Investing, GrowthStocks, InsiderBuying, Investing, PetFoodStocks, StockMarket, StocksToWatch, WallStreet
Illustration of a retro slot machine with dollar signs, stock charts, and dice on the reels, symbolizing insider buying and risk-taking at Penn Entertainment.

Penn Entertainment: A Double-Down That’s Finally Paying Off?

Penn Entertainment ($PENN) is showing signs of life — insiders are doubling down, revenues are climbing, and digital bets are growing fast. With shares rebounding, is it time to follow the high-rollers or step back from the table? 🎰📈

Read entire article

Tags: Buybacks iCasino, casino stocks, CasinoStocks, CEO insider buying, contrarian investing, Contrarian Play, Contrarian Stocks, ContrarianPlays, ContrarianStocks, ESPN BET, ESPNBET, Funanc1al, Funanc1al Edge, Funanc1al for Investors, Funanc1al Investing, Funanc1alEdge, Funanc1alInvesting, insider buying, InsiderBuying, Institutional Ownership, Investing, Jay Snowden, Online Casino, PENN, PENN Entertainment, PENN Stock, PennEntertainment, Sports Betting, SportsBetting, Stock Market Humor, StockMarket, StocksToWatch, theScore, Turnaround Stocks
Cartoon-style illustration of Ligand Pharmaceuticals' building transforming into a giant molecule, with a Nasdaq bell ringing above and two smiling executives tossing cash into a biotech flask labeled “Royalty Engine.”

Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!

Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?

Read entire article

Tags: BiotechHumor, BiotechInvesting, CEO Buys, CEO insider buying, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, ContrarianStocks, Funanc1al, Funanc1al for Investors, Funanc1al Investing, Funanc1alInvesting, InsiderBuys, LGND, LGND Stock, LigandPharma, MoleculeMoney, NasdaqBell, PharmaRoyalties, RoyaltyBiotech, RoyaltyEngine, ScienceStocks, SpeculativeBiotech, TurnaroundPlays, VikingTherapeutics, WallStreetHedgeFunds, ZELSUVMI